Sunitinib (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sunitinib" in Italian language version.

refsWebsite

Global rank Italian rank

8doi.org

2^nd place

7^th place

7oadoi.org

799^th place

22^nd place

6nih.gov

4^th place

9^th place

1thelancet.com

2,393^rd place

2,216^th place

1clinicaltrials.gov

5,225^th place

5,296^th place

1fda.gov

447^th place

644^th place

1curehunter.com

low place

1nytimes.com

7^th place

19^th place

1genengnews.com

low place

1bbc.co.uk

8^th place

23^rd place

1telegraph.co.uk

30^th place

64^th place

1nice.org.uk

3,258^th place

8,692^nd place

1pbs.gov.au

low place

bbc.co.uk

news.bbc.co.uk

BBC news - Aug 2008 - 'We'll sell our house for this drug'

clinicaltrials.gov

"Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma"

curehunter.com

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | CureHunter

doi.org

dx.doi.org

Gastrointestinal stromal tumor: a clinical overview, in Hematol. Oncol. Clin. North Am., vol. 23, n. 1, February 2009, pp. 69–78, viii, DOI:10.1016/j.hoc.2008.11.006, PMID 19248971.
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations, in Expert Rev Anticancer Ther, vol. 9, n. 6, June 2009, pp. 831–8, DOI:10.1586/era.09.34, PMID 19496720.
Sunitinib in solid tumors, in Expert Opin Investig Drugs, vol. 18, n. 6, June 2009, pp. 821–34, DOI:10.1517/13543780902980171, PMID 19453268.
(EN) George D. Demetri, Allan T. van Oosterom e Christopher R. Garrett, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, in The Lancet, vol. 368, n. 9544, 14 ottobre 2006, pp. 1329–1338, DOI:10.1016/S0140-6736(06)69446-4. URL consultato il 25 marzo 2020.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, in J. Clin. Oncol., vol. 27, n. 22, August 2009, pp. 3584–90, DOI:10.1200/JCO.2008.20.1293, PMID 19487381.
DT Alexandrescu, R McClure e H Farzanmehr, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in Journal of Clinical Oncology, vol. 26, n. 24, 2008, pp. 4047–8, DOI:10.1200/jco.2008.18.3525, PMID 18711201.
Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules., in J Urol, vol. 191, n. 3, March 2014, pp. 611–618, DOI:10.1016/j.juro.2013.08.090, PMID 24018239.
Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability, in J Mol Med (Berl), vol. 89, n. 6, Jun 2011, pp. 595–602, DOI:10.1007/s00109-011-0737-3.

fda.gov

FDA approves Sutent for rare type of pancreatic cancer

genengnews.com

GEN | News Highlights: FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors

nice.org.uk

pathways.nice.org.uk

(EN) Renal cancer - NICE Pathways, su pathways.nice.org.uk. URL consultato il 14 marzo 2017.

nih.gov

ncbi.nlm.nih.gov

Gastrointestinal stromal tumor: a clinical overview, in Hematol. Oncol. Clin. North Am., vol. 23, n. 1, February 2009, pp. 69–78, viii, DOI:10.1016/j.hoc.2008.11.006, PMID 19248971.
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations, in Expert Rev Anticancer Ther, vol. 9, n. 6, June 2009, pp. 831–8, DOI:10.1586/era.09.34, PMID 19496720.
Sunitinib in solid tumors, in Expert Opin Investig Drugs, vol. 18, n. 6, June 2009, pp. 821–34, DOI:10.1517/13543780902980171, PMID 19453268.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, in J. Clin. Oncol., vol. 27, n. 22, August 2009, pp. 3584–90, DOI:10.1200/JCO.2008.20.1293, PMID 19487381.
DT Alexandrescu, R McClure e H Farzanmehr, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in Journal of Clinical Oncology, vol. 26, n. 24, 2008, pp. 4047–8, DOI:10.1200/jco.2008.18.3525, PMID 18711201.
Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules., in J Urol, vol. 191, n. 3, March 2014, pp. 611–618, DOI:10.1016/j.juro.2013.08.090, PMID 24018239.

nytimes.com

In Gene Sequencing Treatment for Leukemia, Glimpses of the Future, su nytimes.com.

oadoi.org

Gastrointestinal stromal tumor: a clinical overview, in Hematol. Oncol. Clin. North Am., vol. 23, n. 1, February 2009, pp. 69–78, viii, DOI:10.1016/j.hoc.2008.11.006, PMID 19248971.
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations, in Expert Rev Anticancer Ther, vol. 9, n. 6, June 2009, pp. 831–8, DOI:10.1586/era.09.34, PMID 19496720.
Sunitinib in solid tumors, in Expert Opin Investig Drugs, vol. 18, n. 6, June 2009, pp. 821–34, DOI:10.1517/13543780902980171, PMID 19453268.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, in J. Clin. Oncol., vol. 27, n. 22, August 2009, pp. 3584–90, DOI:10.1200/JCO.2008.20.1293, PMID 19487381.
DT Alexandrescu, R McClure e H Farzanmehr, Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib, in Journal of Clinical Oncology, vol. 26, n. 24, 2008, pp. 4047–8, DOI:10.1200/jco.2008.18.3525, PMID 18711201.
Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules., in J Urol, vol. 191, n. 3, March 2014, pp. 611–618, DOI:10.1016/j.juro.2013.08.090, PMID 24018239.
Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability, in J Mol Med (Berl), vol. 89, n. 6, Jun 2011, pp. 595–602, DOI:10.1007/s00109-011-0737-3.

pbs.gov.au

Australian Pharmaceutical Benefits Scheme - Sutent

telegraph.co.uk

Daily Telegraph, Feb 4, 2009

thelancet.com

(EN) George D. Demetri, Allan T. van Oosterom e Christopher R. Garrett, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, in The Lancet, vol. 368, n. 9544, 14 ottobre 2006, pp. 1329–1338, DOI:10.1016/S0140-6736(06)69446-4. URL consultato il 25 marzo 2020.